New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|November 8, 2013
Comparing Treatment Options in Ovarian Cancer
Author(s)James T. Thigpen, MD
James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.
Advertisement
James T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Clinical Pearls
- In ovarian cancer studies, researchers cannot control what therapies a patient will receive following progression on a study therapy
- These additional lines of therapy have an impact on survival, making it difficult to make an accurate comparison of therapies
- Using progression-free survival (PFS) as an endpoint may allow for a clean comparison
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
5